My Cart

HLA-A*0201 | B2M

Product Inquiry

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
LBL-019LBL-019Phase 2 ClinicalNeoplasms
Details
BI-1910BI-1910Phase 2 ClinicalBioinvent International AbSolid tumours; Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung
Details
BITR-2101BITR-2101; BIR-2101; BITT2101; BITT-2101Phase 1 ClinicalInfections; Neoplasms; Lymphoma, Non-Hodgkin
Details
NBL-020Phase 1 ClinicalShanghai Xinshi Biological Medicine Co LtdSolid tumours; Neoplasms
Details
SIM1811-03SIM1811-03; SIM0235; SIM-235Phase 1 ClinicalJiangsu Simcere Pharmaceutical Co LtdSolid tumours; Neoplasms; Lymphoma, T-Cell, Cutaneous
Details
HFB-2003(HiFiBiO Therapeutics)HFB-200301; HFB-2003Phase 1 ClinicalHiFiBiO TherapeuticsSkin Melanoma; Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Mesothelioma; Sarcoma; Testicular Neoplasms; Germinoma; Melanoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
Recombinant human type II tumor necrosis factor receptor-antibody fusion protein(Hisun Biological)ApprovedMainland ChinaPsoriasis; Arthritis, Rheumatoid; Spondylitis, AnkylosingHisun Biopharmaceutical Co Ltd2015-04-09Spondylitis, Ankylosing; Arthritis, Rheumatoid; Psoriasis
Details
  • Product Inquiry
  • Marketed Drug Information
  • Clinical Drug Information